Kornimate/medical-research-clean huggingface dataset:
effect of krill oil on cognitive function in adults

Conditions: Subjective Memory Impairment

Summary: the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of krill oil on cognitive function in adults with subjective memory impairment for 12 weeks.

previous animal studies have indicated that krill oil may have the ability to improve cognitive function. therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of krill oil on cognitive function in adults with subjective memory impairment for 12 weeks; the safety of the compound are also evaluate. the investigators examine chemical and metabolic parameters, and cognitive function at baseline, as well as after 6 and 12 weeks of intervention. one hundred adults were administered either 500 mg of krill oil or a placebo each day for 12 weeks.

Eligibility criteria:
inclusion criteria: * global deterioration scale (gds) 2 or 3 exclusion criteria: * abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dl) * diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dl) * history of viral hepatitis or cancer * uncontrolled hypertension * history of serious cardiac disease such as angina or myocardial infarction * history of gastrectomy * history of medication for psychiatric disease * administration of oriental medicine including herbs within the past 4 weeks
lung hyperinflation and response to pulmonary vasodilator therapy

Conditions: Copd; Hypertension, Pulmonary; Hyperdistention

Summary: the goal of this retrospective observational study is to evaluate if lung distension disorders can be a predictive factor of bad response to vasodilator therapy in patients with pulmonary hypertension (ph) associated with chronic obstructive pulmonary disease (copd). the study will include all patients from the hospital, followed for pulmonary hypertension associated with copd under vasodilator therapy between 2015 and 2021.

the goal of this retrospective observational study is to evaluate if lung distension disorders can be a predictive factor of bad response to vasodilator therapy in patients with pulmonary hypertension (ph) associated with chronic obstructive pulmonary disease (copd). the study will include all patients from the hospital, followed for ph associated with copd under vasodilator therapy between 2015 and 2021. it will evaluate patients' lung hyperinflation according to the rv/tlc ratio and their response to treatment.

Eligibility criteria:
inclusion criteria: * patients with copd regardless of severity defined as a fev1/fvc ratio less than 0.70 and the presence of a risk factor (smoke exposure with at least a 10 pack-year history, or professional exposition) diagnosed with ph according to esc/ers 2022 classification and in whom vasodilator therapy has been initiated exclusion criteria: * other known concomitant lung disease (interstitial lung disease, cystic lung disease, mucoviscidosis...) * thoracic pathology such as kyphoscoliosis * pleural effusion (unless part of pulmonary veno-occlusive disease) * a large tumor lung mass * efr missing or uninterpretable because difficult to perform * initiation of calcium channel blockers * surgical treatment in chronic thrombo-embolic pulmonary hypertension * no follow-up evaluation (lost to follow-up or died before reassessment)

Keywords: copd pulmonary distension lung distension disorders pulmonary hypertension vasodilator therapy
a population-based study of macular choroidal neovascularization in a chinese population

Conditions: Geographic Atrophy; Wet Macular Degeneration; Retinal Drusen

Summary: to investigate pathomorphological and functional variations of choroidal neovascularization (cnv) in age-related macular degeneration (amd) in a chinese population using optical coherence tomography (oct) to find which kinds of fundus characteristics indicated exudative amd.

this population-based study enrolled 59 patients (\>45 years old; 70 eyes) with early and intermediate-stage amd from youyi street, baoshan district, shanghai, china. comprehensive standardized ophthalmic examinations included visual acuity, anterior segment analysis by slit lamp, dilated fundus evaluation by direct ophthalmoscopy, 90d handheld lens, fundus photography, fluorescein angiography (ffa), and fast optic disk scans using oct. the macular cnv characteristic profiles in early and intermediate-stage amd were determined by oct. data were obtained at first visit and 6 to 24 months follow-up, and ffa and oct outcomes of early and intermediate-stage amd patients were analyzed.

Eligibility criteria:
inclusion criteria: * adults citizens aged above 45 years exclusion criteria: * lost samples

Keywords: macular degeneration; choroidal neovascularization
effects of extended haemodialysis treatment duration in patients with end-stage renal disease

Conditions: End Stage Renal Disease

Summary: design: prospective randomised cross-over study. fifty-two eligible patients will be randomised to a treatment time of either 6 hours or 4 hours for a period of 24 weeks and following a washout period of 4 weeks, switch to the alternative treatment time for an additional 24 weeks. aims: to examine the feasibility and effect of extended dialysis treatment time, 6 hours thrice weekly, versus the standard, 4 hours thrice weekly, comparing the differences from baseline in outcome measures over a total 12-month period. primary outcome measure 1\]serum albumin secondary outcome measures nutritional status 1. malnutrition-inflammation score 2. dietary intake 3. hand-grip strength 4. energy expenditure quality of life 1. patient reported quality of life and 2. time to recovery from dialysis serum biomarkers 1. bnp 2. troponin 3. mcp-1 others 24- hour ambulatory blood pressure 24-hour accelerometer population: local haemodialysis population of 1200 patients eligibility: minimum 90days on haemodialysis treatment duration: fifty-six weeks


Eligibility criteria:
inclusion criteria: * dialysis dependant for over 90 days exclusion criteria: 1. haemodialysis for less than 90 days 2. patients with anticipated life expectancy less than 6 months secondary to significant morbidity e.g. metastatic malignancy, advanced human immunodeficiency virus 3. patients with acute liver disease; history of underlying haematological condition; 4. elective planned change of renal replacement modality within the 12 months.

Keywords: haemodialysis crossover treatment time nutritional status
efficacy and safety of oral encochleated amphotericin b for the treatment of cryptococcal infection

Conditions: Cryptococcal Infections

Summary: this will be an open label phase i/ii prospective cohort study to determine the efficacy and safety of camb for the treatment and prevention of cryptococcal infection.


Eligibility criteria:
inclusion criteria: * hiv infection, informed consent, cryptococcal infection present, diagnosed by either: csf cryptococcal culture, csf cryptococcal antigen (crag), plasma/serum crag exclusion criteria: * presence of jaundice or known liver cirrhosis, \>72 hours antifungal therapy, pregnancy or breastfeeding, unlikely to attend regular clinic visits

Keywords: amphotericin b cryptococcal
effectiveness of oral acetazolamide, brimonidine tartarate, and anterior chamber paracentesis in intraocular pressure (iop) after bevacizumab

Conditions: Macular Edema; Diabetic Retinopathy; Macular Degeneration

Summary: purpose: to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (iop) variations after intravitreal bevacizumab injection (ivbv). methods: 47 patients scheduled for ivbv (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before ivbv with either 250 mg oral acetazolamide (dia, 9 eyes), anterior chamber paracentesis immediate after ivbv (par, 15 eyes), topic brimonidine tartarate 1 hour before ivbv (bri, 14 eyes), or no pre-treatment ibvb (ctr, 9 eyes). iop will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.


Eligibility criteria:
inclusion criteria: * macular edema exclusion criteria: * pulmonary chronic problems * chronic renal failure * intraocular inflammation * drug or alcohol addiction

Keywords: bevacizumab intra-ocular pressure acetazolamide anterior chamber paracentesis brimonidine macular edema secondary to diabetic retinopathy or macular degeneration
posterior capsule opacification (pco) evaluation of the acrysof sn60at lens vs. sn60wf lens

Conditions: Cataract

Summary: to assess posterior capsule opacification (pco) in patients implanted with either the acrysof sn60at lens or the acrysof sn60wf lens.


Eligibility criteria:
inclusion criteria: * patients with bilateral senile cataracts * age \> 50 years * fit for hospital follow ups * pupils dilating \> 6mm preoperatively * eyes expected to see 6/12 or better postoperatively exclusion criteria: * diabetes * on treatment for glaucoma * other ocular pathology * previous ocular surgery

Keywords: cataract
comparative study of three different testing mechanisms for clostridium difficile

Conditions: Clostridium Difficile

Summary: the purpose of this study is to establish which of the following tests perform best in diagnosing clostridium difficile. pcr, enzyme immunoassays (eia) and c. difficile cytotoxin assay (cta).

this comparative study will be carried out in the hospital microbiology laboratory of a tertiary academic health center, st. joseph's healthcare (sjh) affiliated with mcmaster university, hamilton, on on 500 individual stool samples from patients greater than 12 months of age to determine an efficacy of distinction between current gold standard and other methods of testing for clostridium difficile. this study is required to find a faster test for diagnosis of cdi in order to facilitate prompt treatment and reduce the complications of cdi. identification of infected cases will lead to the enforcement of infection control measures and thereby prevent spread to other susceptible children. this is turn will reduce costs, length of stay, morbidity, and mortality from cdi if instituted correctly.

Eligibility criteria:
inclusion criteria: * patients older than 12 months of age * having diarrhea exclusion criteria: * inadequate volume of sample to perform all three diagnostic tests (less than 3ml * formed stools

Keywords: clostridium difficile
external oblique intercostal plane block vs. wound infiltration for laparoscopic sleeve gastrectomy

Conditions: Obesity

Summary: the morbidity and mortality associated with being overweight or obese have been known to the medical profession since hippocrates, more than 2500 years ago. pain that develops following bariatric surgery may prolong recovery time. most morbidly obese patients have obstructive sleep apnea and cardiac comorbidities. in these patients, prolonged postoperative pain may cause early ambulation and delay performing deep breathing exercises. using regional anesthetic techniques results in less opioid use and better pain management. external oblique internal costal block; it is a new block that provides dermatomal sensory blockage involving t6-t10 in the anterior axillary line and t6-t9 in the midline. it can be used as part of multimodal analgesia in laparoscopic cases. there is no study in the literature regarding the use of external oblique plane block in bariatric surgery yet.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologist's physiologic state i-iii patients * laparoscopic obesity surgery exclusion criteria: * chronic pain bleeding disorders renal or hepatic insufficiency patients on chronic non-steroidal anti-inflammatory medications emergency cases
neurophysiologic changes in patients with bipolar depression

Conditions: Bipolar Depression

Summary: * to examine differences in neurophysiologic parameters between unmedicated patients with bipolar depression and healthy controls * to examine within-subject changes in neurophysiologic parameters in patients with bipolar depression treated with quetiapine

* alterations of neurophysiologic regulation has been suggested in patients with major depressive disorder or bipolar disorders * depressive phase of bipolar disorder shows multi-faceted characteristics different from unipolar depression * quetiapine is an atypical antipsychotic licensed for treatment of bipolar depression * the aim of this study is to investigate the pattern of neurophysiologic dysregulation in bipolar depression and its changes induced by quetiapine treatment

Eligibility criteria:
inclusion criteria: * dsm-iv bipolar disorder i or ii * depressive phase * drug-naive or drug-free exclusion criteria: * serious medical or neurological conditions * dsm-iv substance-related disorders (within 12 months prior to participation) * mentally retarded

Keywords: bipolar depression heart rate variability cardio-respiratory coupling electroencephalography
thoracic paravertebral block with methylene blue visual confirmation for postoperative pain after vats lobectomy

Conditions: Post Operative Pain; Thoracic Cancer

Summary: the goal of this study is to compare the efficacy in controlling postoperative pain of paravertebral block (pvb) with methylene blue visual confirmation and thoracic epidural anesthesia (tea). this is a single center, parallel-group, prospective study. patients will be randomly assigned in a 1:1 ratio to receive either pvb or tea. primary end-point is pain relief measured with postoperative numeric rating scale. the secondary end-points are time to perform tea and pvb, total opioid consumption, postoperative outcomes.

the management of postoperative pain in patients undergoing thoracoscopic lobectomy is a fundamental part of the process of recovery. uncontrolled thoracic pain in the early postoperative period may interfere with the mobilization of the patients, leading to increased morbidity and reduction in the quality of life. thoracic paravertebral block (pvb) is an effective strategy for controlling postoperative pain after video-assisted thoracoscopic (vats) lobectomy, but it may be subjected to a high rate of failure due to incorrect identification of the site of local anesthetic injection. thoracic epidural anesthesia (tea) is considered a reliable technique for regional thoracic anesthesia, however potential side effects may limit its use. herein the investigators reported a new technique using methylene blue as a visual confirmation of the correct anesthetic diffusion during pvb. then, the investigators will compare the efficacy of methylene blue pvb with tea for the management of postoperative pain in patients undergoing vats lobectomy. this is a single center, parallel-group, prospective study. participants will be randomly assigned in a 1:1 ratio to receive either pvb with methylene blue or tea. all participants will receive postoperatively intravenous acetaminophen as additional analgesics and intravenous tramadol as rescue analgesic. primary end-point is pain relief measured with postoperative numeric rating scale at at 1, 12, 24, 48 hours postoperatively. the secondary end-points are: (i) time to perform tea and pvb, (ii) total opioid consumption, (iii) postoperative outcomes (including complications, chest drainage duration and length of hospital stay).

Eligibility criteria:
inclusion criteria: * males and females aged 18 - 85 years old * scheduled to undergo thoracoscopic lobectomy for lung cancer * standardized three-port anterior thoracoscopic approach exclusion criteria: * allergy to any of the drugs used in the study * previous thoracic surgical procedures or lung resection * psychiatric disorders * asa (american society of anesthesiologists) class \> iii * conversion to thoracotomy * lack of written informed consent * participation to other studies * contraindications to epidural analgesia or paravertebral block

Keywords: postoperative pain regional anesthesia thoracoscopy
the technical operations and standard clinical application protocol of cbbct in diagnostic process of breast cancer

Conditions: The Clinical Application Guide of Conebeam Breast CT

Summary: this study intends to recruit about 800 volunteers with 400 malignant cases and 400 benign cases (negative results included). the information acquired from those cases mainly includes: image acquirement parameters, physical examination data of patients, scanning positions, radiological images and diagnosis reports of cbbct, mammography, breast ultrasound, mri (if any), pathologic reports, follow-up reports and the like. the image quality comprehensive evaluation and multi-observer, multi-case diagnostic comparing experiment will be processed. with the pathologic report as gold standard, diagnostic comparing experiment between cbbct and mammography, breast ultrasound, mri will be designed to determine the differences between various lesions' presentation on cbbct and on other approaches with diverse breast conditions (size, density). the problems to be solved in this study include: 1. standardize the scanning positons, equipment parameter settings and other technical essentials based on the comprehensive analysis of image data acquisition, image quality and diverse patients' conditions, so as to guarantee image quality stability. 2. summarize the breast anatomic features, typical and atypical lesions' characteristics on cbbct image based on the analysis of 3d-cbbct data and pathologic results as well as the comparing of cbbct with other approaches, so as to establish the radiological diagnostic standard of cbbct. 3. standardize the application consensus of cbbct based on the image features, data acquisition process and patients' conditions.


Eligibility criteria:
inclusion criteria: * female, older than 35 years. already have mammography, or other standard exams (ultrasound, mri, etc). could participate this trial within 2 weeks after mammography. have the ability of consent inform. exclusion criteria: * during pregnancy or lactation period. patients that may not be capable of prone position, such as patients with scapulohumeral periarthritis, cardiac pacemaker or have recent cardiac surgery. lymphoma patients that under therapy. severe scoliosis.
evaluation of metabolic profile of oc000459

Conditions: Asthma

Summary: an open label study in 9 male and 9 female healthy subjects to determine the pharmacokinetics of parent compound and metabolite after eight days of dosing.

the study will include 9 male and 9 female healthy subjects. following informed consent and satisfactory screening, each will be dosed for seven consecutive days on an outpatient basis with oc000459 50 mg daily taken before breakfast. on the seventh day, subjects will report to the clinical unit. following an overnight fast, blood samples will be drawn for baseline safety and pharmacokinetic measurements and a urine specimen will be obtained for urinalysis and baseline metabolite measurements and subjects will be dosed with 50 mg oc000459. blood samples will then be drawn at selected intervals for 120 hours post dosing and will be analysed for oc000459 parent compound and its metabolite. urine collections will be obtained over the same period to determine the excretion of the metabolite and parent compound in urine.

Eligibility criteria:
inclusion criteria: 1. healthy male and female subjects, any racial group 2. aged 18-55 years inclusive 3. able to comply with the protocol 4. subjects with a body mass index (bmi) of 21-28 (bmi = body weight (kg) / (height (m)2) 5. subjects with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 21 days of the first dose exclusion criteria: 1. a history of gastrointestinal disorder likely to influence drug absorption 2. receipt of any medication including over the counter preparations and vitamins within 14 days of the first study day with the exception of paracetamol up to a maximum of 2 g daily 3. evidence of clinically significant renal, hepatic, cardiovascular or metabolic dysfunction 4. a history of drug or alcohol abuse 5. inability to communicate well with the investigator (i.e., language problem, poor mental development or impaired cerebral function) 6. participation in a clinical study within 3 months of the first dose of study drug. subjects will be checked against the over volunteering prevention system (tops) 7. donation of 450 ml or more blood within 60 days of the first dose of study drug 8. a history of hypersensitivity and/or idiosyncrasy to any of the test compounds or related drugs or excipients employed in this study 9. pregnancy or lactation
endometrial rejuvenation study

Conditions: Infertility of Uterine Origin

Summary: to evaluate the response of the endometrial lining after subcutaneous administration of the medication amd3100. this medication mobilizes stem cells and will be used in a population of infertile women with a thin endometrium who are undergoing frozen-thawed embryo transfer. the investigators will assess associations between response to stem cell mobilization and pregnancy outcomes.

this study seeks to help each participant build a better endometrial lining which is suitable to implantation and maintenance of a healthy pregnancy. while animal models demonstrating the effectiveness of stem cell recruitment on improved endometrial thickness and pregnancy outcomes are plentiful, human studies are lacking. the use of stem cells from the peripheral circulation in humans could potentially allow for enhanced endometrial proliferation. the objective of this study is to perform a prospective randomized, controlled trial to evaluate the response of the endometrial lining after subcutaneous administration of amd3100 (plerixafor). amd3100 is an immunostimulant used to mobilize hematopoietic stem cells in the bloodstream. this intervention will be studied in a population of infertile women with a thin endometrium who have failed previous embryo transfer cycles and are undergoing a frozen-thawed embryo transfer. this study seeks to evaluate both the endometrial response to stem cell mobilization via amd3100 as well as pregnancy outcomes.

Eligibility criteria:
inclusion criteria: 1. patients planning to undergo a frozen-thawed embryo transfer cycle using a single euploid blastocyst. 2. patients who have previously undergone at least 2 unsuccessful frozen-thawed embryo transfer cycles, defined as failure to achieve a clinical pregnancy (visualization of intrauterine gestational sac on ultrasound) or a cancelled embryo transfer cycle due to inadequate endometrial thickness. 3. patients with a diagnosis of thin endometrial lining (less than 6 mm maximum thickness) during at least one prior unsuccessful embryo transfer cycle. 4. initiation of the most recent unsuccessful frozen-thawed embryo transfer cycle with a thin endometrial lining must have occurred after january 1, 2017. exclusion criteria: 1. fewer than 2 prior unsuccessful frozen-thawed embryo transfer cycles. 2. most recent unsuccessful frozen-thawed embryo transfer prior to january 1, 2017. 3. no euploid embryos available for transfer. 4. mullerian anomalies, excluding arcuate uterus 5. submucosal fibroids 6. history of uterine surgery, excluding polypectomy, d\&c, and cesarean section 7. communicating hydrosalpinx without plans for surgical correction prior to study enrollment. 8. failure of patient to agree to enrollment in study with written consent. 9. history of drug sensitivity or adverse reaction to amd3100 (plerixafor). 10. pregnancy